B A C K G R O U N D Description of the condition
Age-related macular degeneration (AMD) is an irreversible, degenerative eye condition involving the central retina. AMD is the leading cause of irreversible blindness in people aged 50 years or older in the UK. It accounts for 50% of blind and partially sighted registrations (Macular Society 2017). Clinically, AMD occurs in two forms: dry-AMD where cellular debris, clinically identifiable as round deposits called drusen accumulate between the choroid and the retina. This is followed by gradual retinal cell death, which can be further complicated by the 'wet' form where blood vessels grow from the choroid underneath the retina. Wet-AMD is more rapidly advancing, and always has some degree of dry-AMD present. The exact cause of the underlying disease process is unknown but the major aetiological factors are oxidative stress, abnormalities in autophagy and heterophagy and innate immune activation exacerbated by genetic predispositions. Dry 
Description of the intervention
Photobiomodulation (PBM) is the process by which low level light technology affects cellular function. Visible to near-infrared (NIR) light wavelength can be delivered by low-level lasers or lightemitting diodes to have beneficial clinical effects.
How the intervention might work
Exposing people with AMD to light ranging from low-intensity visible to NIR (500 nm to 1000 nm), PBM therapy allows for high tissue penetration and offers a non-invasive approach for the treatment of AMD. Mitochondrial cytochrome C oxidase acts as a photoacceptor for NIR irradiation, resulting in the oxidation reduction state of the enzyme. NIR enhances the activity of mitochondrial cytochrome C oxidase and production of adenosine triphosphate (ATP) in the retina leading to a reduction of free radical production and oxidative damage (Sivapathasuntharam 2017 
Why it is important to do this review
Consultation with patients and eye care professionals prioritised the need for a treatment to stop non-exudative AMD progression (James Lind Alliance 2013). Each year in the UK 70,000 people are diagnosed with advanced AMD, a figure which is expected to rise to There is currently no available treatment. An effective and cost-effective intervention would be of considerable benefit to those globally with this untreatable and debilitating condition. PBM offers the possibility of a safe and non-invasive therapy for AMD. Currently there is wide heterogeneity of PBM treatment regimens and uncertainty exists regarding its efficacy. It is important to do this review to obtain an overall estimate of the effectiveness of PBM treatment in nonexudative AMD and to assess any harmful effects.
O B J E C T I V E S
To assess the effects of photobiomodulation for people with nonexudative AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) only in the review.
Types of participants
We will include studies where participants are aged 50 years or older and have non-exudative AMD early, intermediate or late as defined by the Age Related Eye Disease Study (AREDS 2001). Late stages can feature geographic atrophy; a well-demarcated area of retinal pigmented epithelium atrophy with or without central foveal involvement.
Types of interventions
We will include trials where PBM is compared to standard care with or without sham treatment. We will include studies using visible to NIR light (500 nm to 1000 nm) delivered by lowlevel lasers or light-emitting diodes. Trials that have adequately described the PBM therapy parameters in terms of wavelength(s), dose, frequency, duration and coverage will be included. Standard care consists of modifying risk factors; smoking cessation, nutritional advice and supportive measures; referral to low-vision services and visual rehabilitation.
Types of outcome measures Primary outcomes
• Mean best-corrected visual acuity (BCVA) using a logMAR chart at 12 months follow-up.
Secondary outcomes
• Mean best-corrected visual acuity (BCVA) using LogMar chart at three months after treatment (range one to three months).
• Mean contrast sensitivity measured using a Pelli Robson chart at short-(one to three months) and long-term (12 months) follow-up.
• Mean near vision between at short-(one to three months) and long-term (12 months) follow-up.
• Mean low luminance deficit (LLD) score (the difference between low luminance visual acuity and BCVA) measured in logMAR chart units at short-(one to three months) and longterm (12 months) follow-up.
• Mean reading speed at short-(one to three months) and long-term (12 months) follow-up.
• Mean vision-related quality of life score at short (one to three months) and long-term (12 months) follow-up measured using a validated questionnaire.
If these outcomes are measured using alternative techniques, for example other visual acuity or contrast sensitivity charts, we will collect the data and include it in the analysis where possible, e.g. by converting scales. We will report any cost benefit data reported in included studies.
Adverse events
The main complication of PBM is visual loss, especially due to choroidal neovascularisation. We will collect all adverse events such as:
• The proportion of participants with worse vision following PBM therapy. Worse vision is defined by a loss of 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters.
• The proportion of participants who developed new geographic atrophy or progression of geographic atrophy.
• The proportion of participants who developed neovascular macular degeneration.
Search methods for identification of studies Electronic searches
The Cochrane Eyes and Vision Information Specialist will search the following electronic databases for randomised controlled trials and controlled clinical trials. There will be no language or publication year restrictions.
• Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (latest issue) (Appendix 1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch (Appendix 4);
• US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5);
• World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp) (Appendix 6).
Searching other resources
We will review the reference lists of included trial reports and related systematic reviews to identify additional potentially relevant trials. We will contact medical device companies conducting studies on PBM for information about any ongoing or completed but not published clinical trials. We will search abstracts from the annual meetings of the European VitreoRetinal Society, the Macula Society, the Retina Society, subspecialty meetings from the American Academy of Ophthalmology, and the American Society of Retinal Surgeons for ongoing trials.
Data collection and analysis

Selection of studies
Two review authors will screen independently the titles and abstracts resulting from the searches using web-based software (Covidence 2015). We will obtain full-text copies of potentially relevant trials and contact trial investigators for further information if required. Discrepancies between authors as to whether or not studies meet inclusion criteria will be resolved by discussion. We will document the excluded studies and reasons for exclusion. For potentially eligible studies identified on trials registers we will do the following.
• If the study has a completion date more than two years previously, we will look for publications of this trial and contact the investigators if necessary to obtain published or unpublished data from the trial. If eligible, we will include the study in the review irrespective of whether we can identify a publication.
• If the study has a completion date within two years, or in the future, we will document the study in the ongoing studies section.
Data extraction and management
Two review authors will extract data independently using an online form developed by Cochrane Eyes and Vision and using Covidence. We will pre-pilot the data extraction template. We will resolve discrepancies by discussion. Two attempts will be made to contact trial investigators for missing data. Data will be directly imported into Review Manager 5 (RevMan 5) (Review Manager 2014); and the accuracy of the data import will be checked by one author.
Study characteristics
We will collect the following information on study characteristics (Appendix 7).
• Study design: parallel group RCT/within-person RCT/one or both eyes reported
• Participants: country, total number of participants, age, sex, inclusion and exclusion criteria
• Intervention and comparator details: including number of people (eyes) randomised to each group
• Intervention details in terms of wavelength, dose, fluence, intensity, coverage, treatment time, frequency, intervals, total number of sessions and route of administration
• Primary and secondary outcomes as measured and reported in the trials
• Adverse events • Length of follow-up • Date study conducted • Sample size and study power
• Funding and conflicts of interest • Trial registration, if available
Outcome data
We will extract the following data from each included study for intervention and comparator groups separately.
• Mean, standard deviation and number of participants on which outcome measured for continuous variables (visual acuity, contrast sensitivity, reading speed, LLD score).
• Number of events and number of participants on which outcome data collected for dichotomous variables (adverse events).
For multi-arm studies we will use data relevant to our intervention and comparator groups. If two groups contain relevant data we will combine groups using the calculator within RevMan 5. If standard deviation is not available we will use information from confidence intervals and P values, where possible, to estimate it, using the RevMan 5 calculator.
Assessment of risk of bias in included studies
Two review authors will assess independently the risk of bias using Cochrane's 'Risk of bias' tool for assessing risk of bias in each included study (Higgins 2011). We will resolve disagreements by discussion. We will specifically consider and report on the following sources of bias.
• Selection bias (random sequence generation, allocation concealment): was the sequence of allocation generated using a random procedure and was the allocation concealed to people recruiting/enrolling participants and to participants?
• Performance bias (masking of participants and researchers): were the recipients of care unaware of their assigned intervention? Were persons providing care unaware of the assigned intervention?
• Detection bias (masking of outcome assessors). Were persons evaluating outcomes unaware of the assigned intervention?
• Attrition bias: were the rates of follow-up and compliance similar in the groups? Was the analysis by intention to treat and were there any post-randomisation exclusions?
• Selective outcome reporting bias: is there any evidence that the outcomes that were measured have not been reported?
We will grade each domain as low risk of bias, high risk of bias or unclear (lack of information or uncertainty of potential for bias). We will contact trial investigators for clarification of parameters graded as 'unclear'.
Measures of treatment effect
We will calculate the mean difference for the following continuous outcomes: visual acuity, contrast sensitivity, reading speed and LLD score. Where possible, we will check for the skewness of continuous data (Altman 1996). We will calculate the risk ratio for adverse events.
Unit of analysis issues
PBM can be applied unilaterally or bilaterally. Usually it is applied to the affected eye(s). A pilot interventional study showed bilateral drusen size reduction when an ultra low energy nanosecond laser was applied unilaterally in AMD-affected eyes (Guymer 2014; Jobling 2015). Application to only one eye may have an effect in the fellow eye, although the evidence is unclear and beyond the scope of this review.
Eyes and people
Trials may randomise one or both eyes to the intervention or comparator. If people are randomly allocated to treatment but only one eye per person is included in the trial then there will not be a 'unit of analysis' issue. In these cases, we will document how the eye was selected. If people are randomly allocated to treatment but both eyes are included and reported, we will analyse as 'clustered data' i.e. adjust for within-person correlation. If the study is a within-person study, i.e. one eye is randomly allocated to intervention and the other eye receives the comparator, then we will analyse as paired data. We may have to contact the trial investigators for further information to do this.
Cross-over trials
Cross-over trials are feasible; however, the wash out period of the PBM therapy is undetermined which would make designing a cross-over trial difficult. Where cross-over trials are available only relevant outcomes of the first phase will be collected.
Dealing with missing data
If possible, we will conduct an intention-to-treat (ITT) analysis. We will use imputed data if computed by the trial investigators using an appropriate method, but will not impute missing data ourselves. If ITT data are not available, we will do an available case analysis. This assumes that data are missing at random. We will assess whether this assumption is reasonable by collecting data from each included trial on the number of participants excluded or lost to follow-up and reasons for loss to follow-up by treatment group, if reported.
Assessment of heterogeneity
We will examine the overall characteristics of the studies, in particular the type of participants and types of interventions, to assess the extent to which the studies are similar enough to make pooling study results sensible. We will look at the forest plots of study results to see how consistent the results of the studies are, in particular looking at the size and direction of effects. We will calculate I² which is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) (Higgins 2002). We will consider I² values over 50% to indicate substantial inconsistency but will also consider Chi² P value. As this may have low power when the number of studies are few we will consider P < 0.1 to indicate statistical significance of the Chi² test.
Assessment of reporting biases
We will use the 'Risk of bias' assessment tool to look for selective or incomplete reporting. See Assessment of risk of bias in included studies. If there are 10 trials or more included in a meta-analysis, we will construct funnel plots and consider tests for asymmetry for assessment of publication bias, according to Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Data synthesis
We will pool data using a random-effects model in RevMan 5. If there are fewer than three trials in a comparison we will use a fixedeffect model. If there is inconsistency between individual study results such that a pooled result may not be a good summary of the individual trial results -for example, the effects are in different directions or I² > 50% and P < 0.1 -we will not pool the data but will describe the pattern of the individual study results. If there is statistical heterogeneity we may pool the data if all the effect estimates are in the same direction, such that a pooled estimate would seem to provide a good summary of the individual trial results.
Subgroup analysis and investigation of heterogeneity
If there are sufficient trials we will compare the effect of treatment in the following subgroups.
• early, intermediate and late dry-AMD.
Sensitivity analysis
We will examine the impact of excluding studies at high risk of bias in one or more domains.
Summary of findings
We will prepare a 'Summary of findings' Two authors will grade independently the overall certainty of the evidence for each outcome using the GRADE classification (GRADEpro 2015).
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